GENERIC NAME,BRAND NAME,RESTRICTION CRITERIAabacavir,Ziagen,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSabacavir+lamivudine,Kivexa,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSabacavir+lamivudine+zidovudine,Trizivir,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSabatacept,Orencia,Restricted to pediatric inpatients with polyarticular Juvenile Idiopathic Arthritis (JIA) who have had inadequate response to one or more Disease Modifying Antirheumatic Drugs (DMARDs)abiraterone,Zytiga,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAacitretin,Soriatane,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAadefovir,Hepsera,Restricted to indications outlined by BCTSafatinib,Giotrif,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAaldesleukin,Proleukin,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAalemtuzumab,Mabcampath,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAamifostine,Ethyol,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAaminolevulinic acid,Levulan Kerastick,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAamsacrine,AMSA P-D,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAanagrelide,Agrylin,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAanakinra,Kineret,Restricted to pediatric inpatients with systemic onset juvenile idiopathic arthritis (SOJIA) and prominent systemic symptoms OR pediatric inpatients with auto-inflammatory disease / periodic fever syndromesanastrozole,Arimidex,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAantithymocyte globulin (equine),Atgam,Restricted to treatment of aplastic anemia OR pediatric bone marrow transplant (BMT) OR pediatric stem cell transplant (SCT) patientsantithymocyte globulin (rabbit),Thymoglobulin,Restricted to bone marrow transplant (BMT) OR solid organ transplant (SOT) OR stem cell transplant OR aplastic anemia with treatment failure or intolerance to antithymocyte globulin equineapixaban,Eliquis,"Restricted to at risk patients with non_valvular atrial fibrillation, for the prevention of stroke and systemic embolism AND in whom anticoagulation is inadequate following at least a 2 month trial  of warfarin OR for whom anticoagulation using warfarin is contraindicated or not possible due to inability to regularly monitor the patient via International Normalized Ratio (INR) testing in the community (i.e. no access to INR testing services at a laboratory, clinic, pharmacy and at home)"aprepitant,Emend,"Restricted to patients receiving highly emetogenic chemotherapy as per protocols from BCCA, BCCH, or Leukemia/BMT unit"argatroban,Argatroban,Restricted for prophylaxis and treatment of venous thromboembolism (VTE) in patients with heparin induced thrombocytopenia (HIT)aripiprazole,Abilify,Restricted to patient specific diagnosis identified as schizophrenia or other psychosis (not dementia related) PLUS treatment failure or intolerance to another anti-psychotic agentarsenic trioxide,Trisenox,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAasparaginase,"Erwinia, Kidrolase",Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAatazanavir,Reyataz,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSatomoxetine,Strattera,Restricted to treatment of ADHD in pediatricsatovaquone,Mepron,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSaxitinib,Inlyta,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAazacitidine,Vidaza,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAbasiliximab,Simulect,Restricted to indications outlined by BCTS OR leukemia/BMT patients with steroid-refractory acute graft versus host disease (GVHD)beclomethasone,Qvar,Restricted to HIV / AIDS patients with highly active anti-retroviral therapy (HAART)bendamustine,Treanda,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAbevacizumab,Avastin,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAbicalutamide,Casodex,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAbivalirudin,Angiomax,Restricted to use in patients with unstable angina undergoing percutaneous coronary interventions (PCI)bleomycin,Blenoxane,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCA OR as a sclerosing agent for vascular malformations or cystic lesions OR malignant pleural effusions.bortezomib,Velcade,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAbosentan,Tracleer,Restricted to treatment of pulmonary arterial hypertension (PAH)botulinum toxin type A,Botox,Restricted to spasticity OR esophageal sphincter disorders causing dysphagia OR strabismusbuprenorphine+naloxone,Suboxone,Restricted to physicians with a methadone exemption for opioid dependence when methadone is contraindicated or where there is an inadequate response or intolerance to methadonebuserelin,Suprefact,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAbuserelin (depot),Suprefact Depot,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAbusulfan,Myleran,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAcabazitaxel,Jetvana,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAcabergoline,Dostinex,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCA OR for prolactin suppressioncannabidiol+delta-9-tetrahydrocannabinol,Sativex,Restricted to complex/chronic pain or palliative care patientscapecitabine,Xeloda,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAcarbetocin,Duratocin,Restricted to prevention of uterine atony and post-partum hemorrhage following elective caesarean section in women with one or more risk factors for post-partum hemorrhage and may be considered for urgent or emergent caesarean sectioncarboplatin,Paraplatin AQ,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAcarmustine,BiCNU,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAcaspofungin,Cancidas,Restricted to pediatric patients with fungal infections that are known or suspected to be resistant to fluconazole OR in pediatric patients intolerant to fluconazolecefepime,Maxipime,Restricted for use as monotherapy in patients with chemotherapy-induced febrile neutropenia OR in patients with cystic fibrosiscefoxitin,Mefoxin,Restricted to gynecological/obstetrical infections OR neonates/pediatrics OR infections due to Mycobacterium abscessuscetirizine,Reactine,Restricted to pediatricscetuximab,Erbitux,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAchlorambucil,Leukeran,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAciclesonide,"Alvesco, Omnaris",Restricted to patients 6-18 years old OR HIV/AIDS patients with HAART (highly active anti-retroviral therapy)cinacalcet,Sensipar,Restricted to indications outlined by BCPRA AND patients who are registered with BCPRAcisplatin,"Platinol, Platinol A-Q",Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAcladribine,Leustatin,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAclodronate,"Bonefos, Ostac",Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAcobicistat+emtricitabine+elvitegravir+tenofovir,Stribild,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDScolistimethate (colistin),Coly-Mycin,Restricted to treatment of pneumonia in cystic fibrosis patientscollagenase,Santyl,Restricted to debridement of dermal ulcerscrizotinib,Xalkori,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAcyproterone,Androcur,Restricted to forensic patientscytarabine,Cytosar,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAdabigatran,Pradax,Restricted to continuity of care for patients receiving dabigatran prior to admissiondabrafenib,Tafinlar,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAdacarbazine,DTIC,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAdactinomycin,Cosmegen,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAdanaparoid,Orgaran,Restricted for prophylaxis and treatment of venous thromboembolism (VTE) in patients with heparin induced thrombocytopenia (HIT)daptomycin,Cubicin,Restricted to infections caused by gram positive organisms that are resistant to vancomycin and linezolid OR in patients intolerant to vancomycin and linezolid.darbepoetin,Aranesp,Restricted to indications outlined by BCPRA AND patients who are registered with BCPRAdarunavir,Prezista,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSdasatinib,Sprycel,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAdaunorubicin,Cerubidine,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAdegarelix,Firmagon,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAdelaviridine,Rescriptor,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSdexmedetomidine,Precedex,"Restricted to use in Intensive Care Unit, Cardiac Surgery Intensive Care Unit and High Acuity Unit for patients with the following criteria:",,Post-operative cardiovascular/vascular surgery patients requiring mechanical ventilation OR,,"Patients who are being mechanically ventilated with confirmed delirium, and who are refractory, or have had an inadequate response, to a trial of propofol and/or antipsychotic agent OR",,Patients in whom extubation is anticipated within 24-hours (i.e. approximate duration of dexmedetomidine use limited to 24 hours) OR,,Sedation for invasive procedures or awake fibre-optic intubation in critical care patients for whom other agents are not appropriate due to lack of efficacy or adverse effectsdexrazoxane,"Zinecard, Cardioxane",Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAdidanosine,Videx-EC,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSdigoxin immune fab,Digibind,Restricted to use approved by BC Drug and Poison Information Center (DPIC) (part of BC Poison Control Antidote Replacement Programme)docetaxel,Taxotere,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAdolutegravir,Tivicay,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSdonepezil,Aricept,PharmaCare Alzheimer's Drug Therapy Initiative (ADTI) approval is required for new starts in Acute and Residential Care OR continuation of treatment in Residential Care.  UNRESTRICTED for continuation of prior to admission therapy in Acute Care.doxorubicin,Adriamycin,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAdoxorubicin pegylated liposomal,Caelyx,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAefavirenz,Sustiva,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSefavirenz+emtricitabine+tenofovir,Atripla,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSemtricitabine + rilpivirine + tenofovir,Complera,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSemtricitabine+tenofovir,Truvada,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSenalapril,Vasotec,Restricted to pediatricsenfuvirtide,Fuzeon,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSenoxaparin,Lovenox,Restricted to major orthopedic trauma OR spinal cord injury OR acute coronary syndrome (ACS) OR cancer patients OR pediatrics.entecavir,Baraclude,Restricted to indications outlined by BCTSenzalutamide,Xtandi,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAepirubicin,Pharmorubicin,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAepoetin alfa,Eprex,Restricted to indications outlined by BCPRA AND patients who are registered with BCPRA OR to patients pre-approved by BCTS (for cost reimbursement)epoprostenol,Flolan,"Restricted to treatment of pulmonary arterial hypertension (PAH), in patients who have had an inadequate response and/or a contraindication to the non-prostanoid therapies OR aerosolized epoprostenol for hypoxemia secondary to acute respiratory distress syndrome (ARDS) "eribulin,Halaven,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAerlotinib,Tarceva,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAertapenem,Invanz,"Restricted to treatment of documented or suspected infections, involving multi-drug resistant organisms in outpatient or ambulatory setting, where other agents (e.g. piperacillin-tazobactam, ticarcillin-clavulanate, ceftazidime, imipenem) cannot be used due to intolerance, resistance or inconvenience in the ambulatory setting."escitalopram,Cipralex,Restricted to continuity of care for patients receiving escitalopram prior to admissionesomeprazole,Nexium,Restricted to NG use or dysphagia patientsestramustine,"Emcyt, Estracyt",Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAetidronate+calcium,Didrocal,Restricted to residential careetoposide,Vepesid,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAetravirine,Intelence,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSeverolimus,Afinitor,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAexemestane,Aromasin,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAferumoxytol,Feraheme,Restricted to the following indications:,,BCPRA Registered chronic kidney disease patients who are not on dialysis and intolerant to or inadequately treated with oral iron,,Patients who are dialyzing at home:,,Peritoneal dialysis patient inadequately treated with oral iron,,Home hemodialysis patient inadequately treated with oral iron and are not self administering intravenous iron,,Patients who are being dialyzed in a dialysis facility (in- centre or community) and have demonstrated adverse events with and so precludes further treatment with other available intravenous irons,,OR,,Iron deficiency anemia patients with prior adverse reaction to alternative intravenous iron preparationfilgrastim,Neupogen,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCA OR to approval of the Centre for Excellence (CFE) in HIV/AIDS OR Cell Separator Unit donorsfludarabine,Fludara,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAfludarabine,Fludara,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAfluorouracil,"5-FU,Efudex",Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAflutamide,Euflex,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAfluvastatin,Lescol,Restricted to HIV/AIDS patients with HAART (highly active anti-retroviral therapy)fomepizole,Antizol,Restricted to use approved by BC Drug and Poison Information Center (DPIC) (part of BC Poison Control Antidote Replacement Programme)fondaparinux,Arixtra,Restricted to unstable angina (UA) OR non-ST elevation myocardial infarction (NSTEMI) OR medically managed patients with ST elevation myocardial infarction (STEMI) [not treated with percutaneous coronary intervention (PCI) or thrombolysis] OR prophylaxis and treatment of venous thromboembolism (VTE) in patients with heparin induced thrombocytopenia (HIT)fosamprenavir,Telzir,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSfosaprepitant,Emend IV,Restricted to BCCA protocols for prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy who are unable to swallow oral tabletsfosfomycin,Monurol,Restricted to treatment of acute uncomplicated cystitis caused by susceptible organisms with demonstrated resistance and/or intolerance to all other oral agentsfosphenytoin,Cerebyx,Restricted to pediatricsgalantamine,Reminyl,PharmaCare Alzheimer's Drug Therapy Initiative (ADTI) approval is required for new starts in Acute and Residential Care OR continuation of treatment in Residential Care.  UNRESTRICTED for continuation of prior to admission therapy in Acute Care.ganciclovir,Cytovene,"Restricted to use in HIV/AIDS, transplant, hematology, oncology, ophthalmology patients, or for congenital cytomegalovirus"gefitinib,Iressa,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAgemcitabine,Gemzar,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAgoserelin,Zoladex LA,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAidarubicin,Idamycin,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAifosfamide,Ifex,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAimatinib,Gleevec,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAimipenem+cilastatin,Primaxin,"Restricted to treatment of documented or suspected infections involving multi-drug resistant organisms where other agents (e.g. piperacillin-tazobactam, ticarcillin-clavulanate, ceftazidime) cannot be used due to intolerance or resistance"indinavir,Crixivan,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSinsulin detemir,Levemir,Restricted to pediatric patients with diabetes mellitusinterferon alfa (compounded from IV),,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAinterferon alfa-2b,Intron-A,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAipilimumab,Yervoy,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAirinotecan,Camptosar,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAisotretinoin,Accutane,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAlacosamide,Vimpat,Restricted to the following criteria:,,Adjunctive therapy for medically refractory partial-onset epilepsy,,"Adjunctive therapy for refractory status epilepticus where other suitable anti-epileptic agents (such as phenytoin, midazolam, phenobarbital, levetiracetam) have been ineffective, not tolerated or not appropriate.",,Continuity of care for patients receiving lacosamide for epilepsy prior to admission.,,Lacosamide IV is restricted to patients unable to take lacosamide POlamivudine,3TC,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDS OR hepatitis B prophylaxis in patients with a proven-negative HIV test who are immunocompromized (solid organ transplant (SOT) or bone marrow transplant (BMT) or chemotherapy) OR treatment in those with liver failure due to Hepatitis B.lamivudine+zidovudine,Combivir,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSlansoprazole,"Prevacid, Fastabs",Restricted to pediatricslanthanum carbonate,Fosrenol,Restricted to indications outlined by BCPRA AND patients who are registered with BCPRAlapatinib,Tykerb,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAlenalidomide,Revlimid,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAletrozole,Femara,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAleucovorin,Lederle Leucovorin,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAleuprolide,Lupron,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAleuprolide (depot),"Eligard, Lupron Depot",Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAlevocarnitine,Carnitor,Restricted to metabolic disorderslinagliptin,Trajenta,Restricted to combination treatment for type 2 diabetes mellitus when insulin NPH is not an option AND after inadequate glycemic control on maximum tolerated doses of metformin AND a sulfonylurealinezolid,Zyvox,Restricted to infections caused by gram positive organisms that are resistant to vancomycin or in patients intolerant to vancomycin.lomustine,CeeNU,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAlopinavir+ritonavir,Kaletra,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSlovastatin,Mevacor,Restricted to HIV/AIDS patients with HAART (highly active anti-retroviral therapy)magnesium hydroxide+mineral oil,Magnolax,Restricted to patients with eating disorder,,(Automatic Therapeutic Interchange to magnesium hydroxide suspension at same dose and frequency in other patients)maraviroc,Celsentri,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSmechlorethamine,Mustargen,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAmelatonin,RX Balance,Restricted to pediatricsmelphalan,Alkeran,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAmeperidine,Demerol,Restricted to treatment of drug- or blood product-induced rigors and post-operative shiveringmeropenem,Merrem,"Treatment of documented or suspected infections involving multi-drug resistant organisms where other agents (e.g. piperacillin-tazobactam, ticarcillin-clavulanate, ceftazidime, imipenem) cannot be used due to intolerance or resistance",,OR,,"For the following indications/populations: CNS infections, cystic fibrosis, pediatric patients, febrile neutropenia"methadone,Metadol,Restricted to physicians with a full or temporary methadone exemption for opioid dependence or for analgesia (as per Section 56 of the Controlled Drugs and Substances Act)methyl aminolevulinate,Metvix,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAmethylnaltrexone,Relistor,Restricted to patients with opioid-induced constipation where conventional laxative treatments have failed or are not appropriate for patient circumstancesmicafungin,Mycamine,Restricted to fungal infections that are known or suspected to be resistant to fluconazole OR in patients intolerant to fluconazolemitomycin,Mutamycin,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCA OR ophthalmic surgical proceduresmitotane,Lysodren,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAmitoxantrone,Novantrone,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCA OR to treatment of multiple sclerosis OR to treatment of neuromyelitis optic (NMO or Devic's syndrome)mometasone,Nasonex,Restricted to pediatrics age 3 to 12mycophenolate mofetil,Cellcept,Restricted to solid organ transplant (SOT) OR bone marrow transplant (BMT) OR to indications outlined by BC Provincial Renal Agency (BCPRA) BCPRA Glomerulonephritis Formularymycophenolate sodium,Myfortic,Restricted to indications outlined by BCTS.,,The indications for Mycophenolate Sodium (Myfortic¬) will be as follows:,,Patients who have intolerance to the gastro-intestinal side effects of CellCept¬.,,Out-of-province patients who are receiving Myfortic¬ and have returned to British Columbia for follow-upnelfinavir,Viracept,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSnevirapine,"Viramune, Viramune XR",Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSnifedipine,Adalat,Restricted to obstetric indicationsnilotinib,Tasigna,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAnilutamide,Anandron,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAnitrazepam,Mogadon,Restricted to pediatricsoctreotide long acting,Sandostatin LAR,Restriced to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAomeprazole,Losec,Restricted to pediatrics OR pregnancy OR breastfeedingondansetron,Zofran,"Restricted to patients unable to tolerate other available dosage forms (tablet, liquid, injection)"oseltamivir,Tamiflu,Restricted to approval of the Medical Health Officer (MHO) for prophylaxis of influenza-like illness (ILL). UNRESTRICTED for treatment of influenza-like illness (ILL).oxaliplatin,Eloxatin,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCApaclitaxel,Taxol,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCApaclitaxel-nab (nano albumin bound),Abraxane,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCApaliperidone (Invega Sustenna),Invega Sustenna,Restricted to either,,Continuation of prior to admission therapy OR,,Paliperidone initiated by Psychiatry for patients who meet the following PharmaCare Special Authority criteria:,,Management of the manifestations of schizophrenia or related psychotic disorders in:,,Patients who have tried oral paliperidone or risperidone PLUS at least one other antipsychotic agent PLUS continue to be inadequately controlled at maximally-tolerated dose OR,,Patients who are currently receiving a conventional depot antipsychotic PLUS experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia OR,,Patients with a history of non-adherence to antipsychotic medications resulting in important negative outcomes such as repeated hospitalizationspaliperidone (Invega),Invega,Restricted to intolerability of other antipsychotic agentspalivizumab,Synagis,Restricted to respiratory syncytial virus (RSV) prophylaxis as per provincial criteriapanitumumab,Vectibix,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAparaldehyde,,Restricted for use in emergency management of paediatric status epilepticusparomomycin,Humatin,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSpazopanib,Votrient,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCApeginterferon alfa-2a,Pegasys,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCApemetrexed,Alimta,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCA"pentamidine isethionate(Pentacarinat,Pneumopent)","Pentacarinat(pentamidine isethionate), Pneumopent(pentamidine isethionate)",Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDS OR for PCP prophylaxis in patients allergic or intolerant to cotrimoxazolepertuzumab,Perjeta,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAphospholipid+surfactant-associated proteins,Bles (Bovine Lipid Extract Surfactant),Restricted to neonatesporfimer,Photofrin,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAposaconazole,Posanol,Restricted to the prophylaxis or treatment of invasive fungal infections in patients 13 years of age and older who can tolerate a full fat meal for the following indications:,,Prophylaxis of invasive fungal infections in:,,"Neutropenic patients, where neutropenia is present for 10 days or longer, plus one of the following:",,"Colonized with Aspergillus species, and/or receiving corticosteroids>1mg/kg/day.",,Acute Myeloid Leukemia or Myelodysplastic Syndrome receiving induction chemotherapy;,,Acute lymphocytic leukemia,,BurkittÍs Lymphoma,,Allogeneic stem cell transplant patients with steroid- refractory graft-versus-host-disease treated with intensive immunosuppressive therapy,,"Treatment of invasive fungal infections, including zygomycetes, in leukemia/bone marrow transplant patients:",,"Intolerant or resistant to other appropriate antifungals (e.g. amphotericin B, voriconazole, itraconazole, micafungin), or",,Where oral step down therapy is appropriate and cost effectiveprocarbazine,Matulane,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAquinagolide,Norprolac,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCArabies immune globulin,"Hyperrab, Imogam",Restricted to use approved by the Medical Health Officerrabies vaccine,Imovax Rabies,Restricted to use approved by the Medical Health Officerraltegravir,Isentress,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSraltitrexed,Tomudex,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCArasburicase,Fasturtec,Restricted to treatment of acute or at high risk of tumour lysis syndrome when other therapeutic options are not suitableribavirin,Virazole,Restricted to treatment of Respiratory Syncytial Virus (RSV) infectionsrilpivirine,Endurant,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSrisperidone,Risperdal Consta,Restricted to patients who have PharmaCare Special Authority approvalritonavir,Norvir,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSrituximab,Rituxan,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCA; OR adjunct therapy in kidney transplantation for refractory biopsy-proven antibody-mediated rejection; OR indications outlined by BCPRA AND patients who are registered with BCPRArivaroxaban,Xarelto,Restricted for continuation of therapy in patients who were on rivaroxaban prior to admission,,OR,,for prophylaxis of venous thromboembolism (VTE) following elective total hip replacement surgery (up to 35 days) or elective total knee replacement surgery (up to 14 days),,OR,,Patients who meet the following criteria:,,"At risk patients with non-valvular atrial fibrillation, for the prevention of stroke and systemic embolism AND in whom anticoagulation is inadequate following at least a 2 month trial of warfarin",,OR,,"for whom anticoagulation using warfarin is contraindicated or not possible due to inability to regularly monitor the patient via International Normalized Ratio (INR) testing in the community (i.e. no access to INR testing services at a laboratory, clinic, pharmacy and at home)"rivastigmine,Exelon,PharmaCare Alzheimer's Drug Therapy Initiative (ADTI) approval is required for new starts in Acute and Residential Care OR continuation of treatment in Residential Care.  UNRESTRICTED for continuation of prior to admission therapy in Acute Care.rosuvastatin,Crestor,Restricted to HIV/AIDS patients with HAART (highly active anti-retroviral therapy)ruxolitinib,Jakavi,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAsaquinavir,Invirase,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSsevelamer,Renagel,Restricted to indications outlined by BCPRA AND patients who are registered with BCPRAsildenafil,"Viagra, Revatio",Restricted to treatment of pulmonary arterial hypertension (PAH)simvastatin,Zocor,Restricted to HIV/AIDS patients with HAART (highly active anti-retroviral therapy)sirolimus,Rapamune,Restricted to solid organ transplant (SOT) OR bone marrow transplant (BMT)SMOF lipid,SMOFlipid,Restricted to pediatric patientssodium ferric gluconate complex,Ferrlecit,Restricted to indications outlined by BCPRA AND patients who are registered with BCPRAsodium thiosulfate,,Restriced to the treatment of calciphylaxissomatropin,Humatrope,Restricted to PharmaCare approved indicationssorafenib,Nexavar,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAstavudine,Zerit,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSstreptozocin,Zanosar,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAsunitinib,Sutent,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAtacrolimus,"ADVAgraf, Prograf",Restricted to solid organ transplant (SOT) OR bone marrow transplant (BMT) OR to indications outlined by BC Provincial Renal Agency (BCPRA) BCPRA Glomerulonephritis Formularytamoxifen,Tamofen,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAtemozolomide,Temodal,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAtemsirolimus,Torisel,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAteniposide,Vumon,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAtenofovir,Viread,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDS OR indications outlined by BCTStestosterone enanthate,Delatestryl,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAthioguanine,Lanvis,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAthyrotropin alfa,Thyrogen,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAticagrelor,Brilinta,Restricted to the following criteria:,,For continuity of care in patients who are using ticagrelor in the community,,As per PharmaCare criteria for physicians who have signed off on the Collaborative Prescribing Agreement,,,,PharmaCare Criteria:,,"To be taken in combination with ASA 75 mg _ 150 mg daily for patients with acute coronary syndrome (i.e., ST elevation myocardial infarction [STEMI], non-ST elevation myocardial infarction [NSTEMI] or unstable angina [UA]) with ONE of the following:",,Failure on optimal clopidogrel and ASA therapy as defined by definite stent thrombosis or recurrent STEMI or NSTEMI or UA after prior revascularization via percutaneous coronary intervention (PCI),,OR,,STEMI and undergoing revascularization via PCI,,OR,,NSTEMI or UA and high risk angiographic anatomy and undergoing revascularization via PCIticarcillin+clavulanate,Timentin,Restricted to treatment of Stenotrophomonas maltophilia infections when other agents cannot be used due to intolerance or resistancetigecycline,Tygacil,Restricted for use as a last line for patients with multi-drug resistant organism infections or intolerance to other antibioticstipranavir,Aptivus,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDStopotecan,Hycamtin,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAtrastuzumab,Herceptin,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAtrastuzumab emtansine,Kadcyla,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAtretinoin,Vesanoid,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAvalganciclovir,Valcyte,"Restricted to use in HIV/AIDS, transplant, hematology, oncology, or ophthalmology patients"valine,L-valine,Restricted to inborn errors of metabolismvemurafenib,Zelboraf,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAverteporfin,Visudyne,Restricted to wet macular degeneration only on provision of funding by the Ministry of Healthvinblastine,Velbe,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAvincristine,Oncovin,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAvinorelbine,Navelbine,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAvismodegib,Erivedge,Restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCAvoriconazole,VFEND,Restricted to prophylaxis or treatment of aspergillus OR scedosporium OR fusarium OR in patients intolerant to or isolate resistant to amphotericin B deoxycholate or fluconazole. zanamivir,Relenza,Restricted to approval of the Medical Health Officer (MHO) for treatment or prophylaxis of influenza-like illness (ILL) unresponsive to other antiviralszidovudine,Retrovir,Restricted to approval of the Centre for Excellence (CFE) in HIV/AIDSziprasidone,Zeldox,Restricted to patient specific diagnosis identified as schizophrenia or other psychosis (not dementia related) PLUS treatment failure or intolerance to another anti-psychotic agentzoledronic acid,Zometa,Restricted to treatment of osteogenesis imperfecta